SEC Form 4 · accession 0001140361-17-012938
REPLIGEN CORP · RGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas F Ryan Jr.
Director
Period of report
Mar 20, 2017
Accepted (ET)
Mar 22, 2017 · 4:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000730272
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 20, 2017 | M | 4,000 | $3.22 | A | 12,594 | D | |
| Common StockF1 | Mar 20, 2017 | S | 4,000 | $34.8303 | D | 8,594 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.22 | Mar 20, 2017 | M | 4,000 | D | — | Dec 15, 2021 | Common Stock | 4,000 | 1,000 | D |
Explanation of responses
- F1$34.8303 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.64 to $35.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2This option is currently exercisable.